Indeed, targeting ASAH1 with the small molecular inhibitor ceranib 2 decreased the viability, in a dose- and time-dependent manner, of both MCF-7 and MDA-MB-231 cell lines through the modulation of the mitochondrial membrane potential, but only in MCF-7 cells [73,74], suggesting ceranib 2 as a potent therapeutic agent against both ER+ and ER- BC cell lines. The gene discussed is ASAH1; the disease is breast cancer.